{"url":"https://newsforagent.com/news/2026-11-16/radnostix-nano-nuclear-duf6-asset-sale","markdown_url":"https://newsforagent.com/news/2026-11-16/radnostix-nano-nuclear-duf6-asset-sale.md","title":"Radnostix to Sell DUF6 Assets to NANO Nuclear for $13.5 Million","headline":"Radnostix Signs $13.5 Million DUF6 Asset Sale to NANO Nuclear as Q3 Revenue Falls 22%","description":"Radnostix agreed to sell its Fluorine Products and DUF6 assets to NANO Nuclear for $13.5 million, pending NRC approval.","section":"Earnings & Results","published_at":"2026-11-16T17:39:43+00:00","modified_at":"2026-11-16T17:39:43+00:00","author":"News Desk","key_takeaways":["Radnostix will sell its Fluorine Products and DUF6 assets to NANO Nuclear Energy for $13.5 million, split between $9.5 million cash and $4 million in restricted NANO Nuclear shares.","Radnostix reported third-quarter revenue of $2.57 million, down 22% from $3.28 million a year earlier, while Theranostics sales rose 15% to $1.71 million.","Radnostix submitted a Type II Drug Master File to the FDA for Sodium Iodide I-131 API in October 2026 and began shipping Gd-153 products in November 2026."],"companies":[{"name":"Radnostix","is_primary":true,"profile_url":null,"website":"https://www.radnostix.com"},{"name":"NANO Nuclear Energy","is_primary":false,"profile_url":"https://akta.pro/company-profiles/000005y/nano-nuclear-energy","website":"https://nanonuclearenergy.com"},{"name":"Lucerno Dynamics","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0003132/lucerno-dynamics","website":"https://lucerno.com"}],"source":{"publisher":"Moomoo","title":"Radnostix, Inc. Reports FY2026 3rd Quarter and Nine Months Results - Theranostics Sales Up 15% Year-over-Year, Signs Agreement to Sell Fluorine Products/DUF6 Assets to Nano Nuclear Energy, Submits Type II DMF for Sodium Iodide I-131 API","url":"https://www.moomoo.com/news/post/1004772544/radnostix-inc-reports-fy2026-3rd-quarter-and-nine-months-results"},"other_sources":[{"publisher":"TradingView","url":"https://www.tradingview.com/news/tradingview:123ee75665ca6:0-radnostix-inc-inis-theranostics-sales-rose-15-year-over-year/"}],"tags":["Earnings & Results","Radnostix","NANO Nuclear Energy","Lucerno Dynamics"],"body_markdown":"Radnostix, Inc. Agreed on September 28, 2026 to sell its Fluorine Products and DUF6 assets to NANO Nuclear Energy Inc. And its subsidiary HALEU Energy Fuel Inc. For $13.5 million, consisting of $9.5 million in cash and $4 million in restricted NANO Nuclear shares. [Moomoo](https://www.moomoo.com/news/post/1004772544/radnostix-inc-reports-fy2026-3rd-quarter-and-nine-months-results) reported the agreement alongside the company's third-quarter results on November 16, 2026. Radnostix, formerly International Isotopes Inc., makes radioisotope products for medical, industrial and research uses, including sodium iodide I-131 for thyroid treatment and calibration standards sold under its RadQual brand.\n\n## Radnostix's DUF6 Sale Terms and Quarterly Results\n\nThe DUF6 Sale covers assets tied mainly to a depleted uranium de-conversion and fluorine extraction plant previously planned for Lea County, New Mexico. Closing depends on conditions including NRC approval of the license transfer and [NANO Nuclear Energy](https://akta.pro/company-profiles/000005y/nano-nuclear-energy) acquiring fee simple title to, or a valid leasehold interest in, the Lea County project site. Radnostix submitted the license transfer application to the NRC on October 22, 2026. NANO Nuclear, a nuclear microreactor developer, said on November 11, 2026 that it would hold a fourth-quarter fiscal 2026 business update webcast on November 30, 2026, according to Aktien.\n\nThird-quarter revenue was $2.57 million, down 22% from $3.28 million a year earlier, and nine-month revenue was $7.62 million, down 25% from $10.17 million. Radnostix attributed the quarterly decline mainly to delays in large Cobalt Products contracts awaiting NRC amendments to its registered sealed source devices and to lower Calibration & Reference Products sales after a global cobalt-57 supply interruption, partly offset by a 15% rise in Theranostics sales. [TradingView](https://www.tradingview.com/news/tradingview:123ee75665ca6:0-radnostix-inc-inis-theranostics-sales-rose-15-year-over-year/) noted the Theranostics increase and the resumption of Gd-153 shipments. The quarterly net loss was $0.84 million, compared with $0.20 million a year earlier.\n\n\"The agreement to sell our Fluorine Products/DUF6 assets to Nano Nuclear Energy, which remains subject to NRC approval and other closing conditions, would allow us to focus on our core radioisotope and medical device businesses,\" said Shahe Bagerdjian, Radnostix's President and Chief Executive Officer.\n\n## Radnostix's Lucerno Deal and Recall Remediation\n\nRadnostix closed its acquisition of key assets from [Lucerno Dynamics](https://akta.pro/company-profiles/0003132/lucerno-dynamics), including the LARA System and ELLEXA Explorer software, in July 2026, Stock Titan reported. In August 2026, Radnostix reported a 27% decline in second-quarter revenue to $2.67 million and a widened net loss of $0.88 million, mainly because of voluntary product recalls and a Cobalt Products shutdown, according to PR Newswire. The same month, Yahoo reported that Radnostix had completed execution of FDA 483 and recall actions and restored capsule inventory.\n\n## Radnostix's Medical Device and Cobalt Timelines\n\nRadnostix targets a first-quarter 2027 roll-out for its EasyFill Iodine Encapsulation System and expects RadVent products to begin commercialization in the first quarter of 2027. The company projects execution of its delayed Cobalt contracts, covering approximately $1.2 million of contracted sales previously slated for the second half of 2026, in the first quarter of 2027, subject to NRC sealed source device amendments. Radnostix is also awaiting formal FDA close-out of its two voluntary recalls, for which documentation was submitted in June 2026.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}